我院采用促肝细胞生长素与大剂量α－Lb基因工程干扰素治疗慢性活动性肝炎30例，并与对照组30例进行比较．结果治疗组有效率为90．0％，明显高于对照组（P＜0.01），且治疗组SB、ALT、A／G、γ球蛋白的复常时间明显短于对照组（P＜0．05），尤其对血清HBV5项标志物的转换与对照组相比也有显著的统计学差异（P＜0．05），提示同时使用2种药物对治疗慢性活动性肝炎具有较高临床价值。 In our hospital, 30 cases of chronic active hepatitis were treated with hepatocyte growth-promoting factor and high-dose α-Lb gene engineering interferon, and compared with 30 cases in control group. Results The effective rate of treatment group was 90.0%, which was significantly higher than that of control group (P <0.01). The recovery time of SB, ALT, A / G and γ globulin in treatment group was significantly shorter than that in control group (P <0. 05). In particular, there was also a significant statistical difference (P <0.05) between the conversion of serum HBV 5 markers and the control group, suggesting that the combination of two drugs has a high clinical value in the treatment of chronic active hepatitis.